Dr. D. P. Devanand is Professor of Clinical Psychiatry and Neurology at the College of Physicians and Surgeons, Columbia University. He completed medical school at Christian Medical College, Vellore, in India, and trained in psychiatry at the National Institute of Mental Health and Neurosciences, Bangalore, India.

He completed psychiatry residency training at S.U.N.Y. Upstate Medical Center, Syracuse, and Yale University School of Medicine. He then did a clinical research fellowship in Biological Psychiatry at Columbia University, and has continued on the faculty at Columbia University since 1987.

Currently, he is Co-Director of the Memory Disorders Center, and Co-Director of the Late Life Depression Clinic, at the New York State Psychiatric Institute. His research studies involve Alzheimer’s disease, geriatric depression and electroconvulsive therapy. His research has helped define the clinical features and treatment response in elderly patients with chronic mild to moderate depression, or dysthymic disorder.

He pioneered studies on the interface between depression and cognitive impairment in the elderly, and he is also known for his research into early diagnostic markers of Alzheimer’s disease and the treatment of behavioral complications in Alzheimer’s disease. He has been principal investigator on several research grants from the National Institute of Aging and the National Institute of Mental Health. He has also been funded by the Alzheimer’s Association, NARSAD, and the Dana Foundation.

He has published over 180 research papers and articles, and is the author of three books.

Education and Training:

Medical School: Christian Medical College, M.D., 1979
Internship: SUNY UpState Medical Center, Psychiatry, 1980 - 1981
Residency: Yale, Psychiatry, 1982 - 1984
Fellowship: Columbia University, Psychiatry Affective Disorders, 1985 - 1987
Board Certifications: American Board of Psychiatry and Neurology
Subspeciality Certifications: Geriatric Psychiatry

Specialties:

• Neuropsychiatry/Cognitive Disorders
• Depression

Contact Information:

Address:
NYS Psychiatric Institute
Room Annex 425 Unit/Box:126
1051 Riverside Drive
New York, NY 10032

Phone: 212-543-5612
Fax: 212-543-5088
dpd3@Columbia.edu

Selected Recent Publications:

• 1. The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease. Devier DJ, Pelton GH, Tabert MH, Liu X, Cuasay K, Eisenstadt R, Marder K, Stern Y, Devanand DP. Int J Geriatr Psychiatry. 2009 Mar 24. [Epub ahead of print] PMID: 19319929 [PubMed - as supplied by publisher]
• 2. Olfactory identification deficits and MCI in a multi-ethnic elderly community sample.Devanand DP, Tabert MH, Cuasay K, Manly JJ, Schupf N, Brickman AM, Andrews H, Brown TR, Decarli C, Mayeux R. Neurobiol Aging. 2008 Oct 27. [Epub ahead of print] PMID: 18963256 [PubMed - as supplied by publisher]
• 3. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH. Biol Psychiatry. 2008 Nov 15;64(10):871-9. Epub 2008 Aug 23. PMID: 18723162 [PubMed - indexed for MEDLINE]
• 4. Depressive symptoms, vascular risk factors, and Alzheimer's disease. Luchsinger JA, Honig LS, Tang MX, Devanand DP. Int J Geriatr Psychiatry. 2008 Sep;23(9):922-8. PMID: 18327871 [PubMed - indexed for MEDLINE]
• 5. Stroke, depression, and functional health outcomes among adults in the community. Goodwin RD, Devanand DP. J Geriatr Psychiatry Neurol. 2008 Mar;21(1):41-6. PMID: 18287169 [PubMed - indexed for MEDLINE]
• 6. Mild Parkinsonian signs are associated with lower olfactory test scores in the community-dwelling elderly. Louis ED, Marder K, Tabert MH, Devanand DP. Mov Disord. 2008 Mar 15;23(4):524-30. PMID: 18098296 [PubMed - indexed for MEDLINE]
• 7. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Pelton GH, Harper OL, Tabert MH, Sackeim HA, Scarmeas N, Roose SP, Devanand DP. Int J Geriatr Psychiatry. 2008 Jul;23(7):670-6. PMID: 18088076 [PubMed - indexed for MEDLINE]
• 8. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ. Neurology. 2007 Mar 13;68(11):828-36. PMID: 17353470 [PubMed - indexed for MEDLINE]
• 9. Validation and optimization of statistical approaches for modeling odorant-induced fMRI signal changes in olfactory-related brain areas. Tabert MH, Steffener J, Albers MW, Kern DW, Michael M, Tang H, Brown TR, Devanand DP. Neuroimage. 2007 Feb 15;34(4):1375-90. Epub 2006 Dec 28. PMID: 17196831 [PubMed - indexed for MEDLINE]
• 10. Olfactory dysfunction as a predictor of neurodegenerative disease. Albers MW, Tabert MH, Devanand DP. Curr Neurol Neurosci Rep. 2006 Sep;6(5):379-86. Review. PMID: 16928347 [PubMed - indexed for MEDLINE]
• 11. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, Devanand DP. Arch Gen Psychiatry. 2006 Aug;63(8):916-24.
• 12. PET network abnormalities and cognitive decline in patients with mild cognitive impairment. Devanand DP, Habeck CG, Tabert MH, Scarmeas N, Pelton GH, Moeller JR, Mensh BD, Tarabula T, Van Heertum RL, Stern Y. Neuropsychopharmacology. 2006 Jun;31(6):1327-34.
• 13. Homocysteine levels, MTHFR C677T genotype, and MRI Hyperintensities in late-onset major depressive disorder. Chen CS, Tsai JC, Tsang HY, Kuo YT, Lin HF, Chiang IC, Devanand DP. Am J Geriatr Psychiatry. 2005 Oct;13(10):869-75. PMID: 16223965 [PubMed - indexed for MEDLINE]
• 14. A 10-item smell identification scale related to risk for Alzheimer's disease. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, Marder K, Albers MW, Stern Y, Devanand DP. Ann Neurol. 2005 Jul;58(1):155-60. PMID: 15984022 [PubMed - indexed for MEDLINE]
• 15. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R. Arch Neurol. 2005 Jun;62(6):975-80. PMID: 15956169 [PubMed - indexed for MEDLINE]
• 16. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. Devanand DP, Nobler MS, Cheng J, Turret N, Pelton GH, Roose SP, Sackeim HA. Am J Geriatr Psychiatry. 2005 Jan;13(1):59-68. PMID: 15653941 [PubMed - indexed for MEDLINE]
• 17. Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele). Scarmeas N, Habeck C, Anderson KE, Hilton J, Devanand DP, Pelton GH, Tabert MH, Flynn J, Park A, Ciappa A, Tycko B, Stern Y. Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):596-605. PMID: 15545327 [PubMed - indexed for MEDLINE]
• 18. An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. Devanand DP, Juszczak N, Nobler MS, Turret N, Fitzsimons L, Sackeim HA, Roose SP. J Geriatr Psychiatry Neurol. 2004 Dec;17(4):219-24. PMID: 15533993 [PubMed - indexed for MEDLINE]
• 19. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, Pelton GH, Tabert MH, Honig LS, Moeller JR, Devanand DP, Stern Y. Neuroimage. 2004 Sep;23(1):35-45. PMID: 15325350 [PubMed - indexed for MEDLINE]
• 20. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. Devanand DP, Adorno E, Cheng J, Burt T, Pelton GH, Roose SP, Sackeim HA. J Affect Disord. 2004 Mar;78(3):259-67. PMID: 15013252 [PubMed - indexed for MEDLINE]